Cosmos Health Announces Growing Momentum for C-Scrub in the United Kingdom; Now Available at Tesco, the UK’s Largest Retailer
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that its antimicrobial cleanser C-Scrub Wash Chlorhexidine 4% is now carried by Tesco, the UK’s largest retailer. This expands C-Scrub’s UK retail footprint, increasing visibility and accessibility via Tesco’s nationwide stores and online platform, and supports future portfolio rollout in Europe.
Positive
- C-Scrub listed at Tesco, the UK market leader with nearly 30% share
- Expanded UK distribution via Tesco's nationwide store network and online platform
- Stronger market credibility and platform for future product rollouts in Europe
Negative
- None.
News Market Reaction – COSM
On the day this news was published, COSM gained 9.53%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.3% during that session. Argus tracked a trough of -5.9% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $15M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
COSM was down 4.77% while peers were mixed: SNYR +0.62%, EDAP +0.65%, QIPT +0.28%, YI -0.37%, and ZYXI -37.34%, indicating stock-specific trading rather than a broad sector move.
Previous Crypto Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Brand portfolio showcase | Positive | -4.8% | Showcased nutraceutical and wellness brands at World Health Expo Dubai. |
| Feb 11 | Crypto investment update | Positive | -2.2% | Expanded digital assets program with $500,000 Bitcoin purchase to $2.5M total. |
| Jan 20 | Operations and robotics | Positive | -5.6% | Reported customer growth, better unit economics, and robotics enabling ~$40M revenue potential. |
| Jan 14 | Analyst coverage | Positive | -4.7% | Zacks initiated coverage with $4.50 valuation and strong revenue growth projections. |
| Jan 05 | Manufacturing agreement | Positive | +3.0% | Libytec PathMuscle manufacturing deal with minimum 591,500 units over five years. |
Recent ‘crypto’-tagged and growth updates have mostly been followed by negative next-day moves, suggesting a pattern of selling into positive headlines.
Over the past few months, Cosmos Health has issued multiple growth-oriented updates. These include international brand showcasing at World Health Expo Dubai, expansion of a digital assets program to $2.5M, operational scaling that could support ~$40M in additional annual revenue, analyst coverage with a $4.50 valuation and revenue projections above $130M by 2027, and a manufacturing deal for PathMuscle with over 1.2M units expected in five years. Despite broadly positive narratives, four of five events saw negative price reactions.
Historical Comparison
Crypto-tagged and growth updates for COSM have averaged a -2.83% next-day move, showing that positive strategic news has often coincided with post-announcement selling.
Crypto-tagged items span brand expansion, digital asset accumulation, operational scaling, external research coverage, and manufacturing agreements, outlining a shift toward branded products, automation, and alternative treasury strategies.
Regulatory & Risk Context
Cosmos Health filed a Form S-3 shelf on Nov 7, 2025, registering up to $200,000,000 of securities, including an at-the-market offering of up to $100,000,000 of common stock via A.G.P. Proceeds are indicated for acquisition of crypto assets as a treasury asset and for general corporate purposes and working capital.
Market Pulse Summary
The stock moved +9.5% in the session following this news. A strong positive reaction aligns with the strategic nature of this announcement, as C-Scrub gained placement with Tesco, a retailer generating over $80 billion in annual revenue and holding nearly 30% UK market share. Historically, however, COSM’s positive ‘crypto’-tagged updates have often seen selling afterward, so investors would have watched whether this pattern persisted and how any capital raised under the $200,000,000 shelf might affect equity holders.
Key Terms
antimicrobial medical
chlorhexidine medical
AI-generated analysis. Not financial advice.
CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced a significant expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine
Tesco is a leading multinational retail group operating across multiple markets and ranked among the top 20 retailers globally, generating over
Expanding distribution through this established and trusted retail platform represents a meaningful advancement in Cosmos Health’s UK growth strategy and significantly enhances C-Scrub’s visibility, accessibility, and market credibility.
C-Scrub Listed on Tesco.com
C-Scrub is a powerful antiseptic wash offering reliable skin disinfectant properties. It is designed to reduce bacteria and help prevent infection, supporting effective skin hygiene. Cosmos Health expects continued momentum for C-Scrub in the UK as it further strengthens retail partnerships and expands its distribution footprint.
Greg Siokas, CEO of Cosmos Health, stated: “C-Scrub’s entry into Tesco represents a pivotal moment for Cosmos. Building on our established online presence with Amazon, securing placement with the UK’s largest retailer significantly enhances our retail presence and strengthens our credibility in the market. Beyond the immediate growth opportunity for C-Scrub, this milestone establishes a powerful platform for the potential rollout of additional products from our portfolio over time, further solidifying our position in the UK and across broader European markets.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4f55c572-5957-454e-81d1-fb1cb2a0ee0d
FAQ
When did Cosmos Health (COSM) announce C-Scrub availability at Tesco?
What does Tesco distribution mean for C-Scrub sales prospects for COSM?
How significant is Tesco as a partner for Cosmos Health (COSM) in the UK?
Will Cosmos Health (COSM) expand other products into Tesco after C-Scrub?
Where can UK customers buy C-Scrub from Cosmos Health (COSM)?
